/

Cara Therapeutics, Inc.

CARA US

CARA USCara Therapeutics, Inc.

United States Composite

0.69

USD

-0.04

(-5.72%)

-2.19EPS Dil.

-0.32P/E

37.59MMarket Cap

Next Earnings

May 13

Held by Insiders

14.59%

Held by Institutions

45.63%

Short % of Float

4.38%

YTD Yield

-79.09%

3Y Yield

-96.79%

5Y Yield

-95.16%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

- -

LT Borrowings

- -

LT Finance Leases

- -

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

153

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

125

101

116

Cash, Cash Equivalents & STI

101

Accounts Receivable, Net

Inventories

Total Current Liabilities

Payables & Accruals

ST Debt

- -

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

0.00%

115.70%

-50.00%

Net Income, GAAP

-193.36%

-277.48%

-40.00%

Free Cash Flow

-205.14%

-250.32%

-18.99%

Total Cash Common Dividend

- -

Total Equity

47.83%

-6.03%

-64.15%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

- -

2022

2023

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-0.47

-0.61

-0.02

-0.63

-1.74

2022

-0.52

-0.08

-0.43

-0.56

-1.59

2023

-0.49

-0.58

-0.52

-0.59

-2.19

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Mr. Christopher A. Posner
Full Time Employees: 55
Sector: Healthcare
Industry: Biotechnology
Address: 400 Atlantic Street Stamford CT United States 06901
Website: www.caratherapeutics.com
Business: Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Company News

Tipranks
7 days ago
Buy Rating Affirmed for Cara Therapeutics: Promising Prospects for Oral Difelikefalin in Notalgia Paresthetica Treatment
Tipranks
9 days ago
Buy Rating Affirmed for Cara Therapeutics Amidst Promising Korsuva Ph 2/3 Program and Market Potential
Tipranks
a month ago
Cara Therapeutics Is Worried About This – Should You Be Worried Too?
Tipranks
a month ago
Cara Therapeutics: Promising Phase 2/3 Trial Progression Fuels Buy Rating

Company Description

CEO: Mr. Christopher A. Posner
Full Time Employees: 55
Sector: Healthcare
Industry: Biotechnology
Address: 400 Atlantic Street Stamford CT United States 06901
Website: www.caratherapeutics.com
Business: Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.